Loading data for ANNX — first visit, this takes a few seconds.

Annexon, Inc. (ANNX)

NasdaqGS: ANNX · 即時價格 · USD

4.87

+0.03 (0.62%)

收盤價： Sep 04, 2026, 8:00 PM

提醒

Alert

股價、關鍵數字和最新消息，都在這一頁。

無可用資料

買價	3.47
市值	923M
營收 (ttm)	n/a
淨利（ttm）	-203M
	1.22
	-1.13
	n/a
	-4.5
P/B (ttm)	4.57
P/S (ttm)	0.00
財報日期	Nov 9, 2026

賣價	4.88
成交量	1,227,542
20 日平均成交量	3,499,950
開盤價	4.81
前收盤價	4.84
當日區間	4.79 - 4.91
52 週範圍	2.10 - 7.18
分析師	n/a
目標價	n/a
股利	n/a
除息日	n/a

關於 ANNX

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic...

[閱讀更多]

產業 Biotechnology

類股 Healthcare

IPO 日期 Jul 24, 2020

員工 92

證券交易所 NasdaqGS

股票代號 ANNX

網站 https://www.annexonbio.com

完整的公司簡介

財務表現

Annexon 在 2025 年的營收為 0，較前一年的 0 增加 undefined%。淨利為 -206.69M，較前期增加 49.56%。

財務報表

財報驚奇

Annexon 已於 Aug 12, 2026 公布季度財報：

營收為 $0 低於預期 $0, 年增 NaN% 成長.
每股盈餘為 -0.28 低於預期 -0.04, 年增 17.65% 成長.

下次財報發布

Annexon, Inc. 的下次財報預計於 Nov 9, 2026, 開盤前。
分析師預估營收 ... 升級

價格為何變動

新聞動態

2 週前 · Simply Wall St.

What Annexon (ANNX)'s Dual-Endpoint ARCHER II Update Means For Shareholders

In August 2026, Annexon reported a higher second-quarter net loss of US$55.35 million but a lower year-to-date loss of US$99.49 million, while updating investors on its ongoing Phase 3 ARCHER II trial...

2 週前 · Motley Fool

Annexon (ANNX) Q2 2026 Earnings Call Transcript

GBS and geographic atrophy programs advance toward 2026-2027 regulatory submissions.

3 週前 · Simply Wall St.

Annexon (ANNX), What Is Behind Its Latest Update?

Annexon (ANNX) stock was in focus after the company updated investors on its late stage pipeline, highlighting a dual primary endpoint for the Phase 3 ARCHER II trial and new Guillain Barré syndrome d...

3 週前 · Moby

Annexon, Inc. Q2 2026 Earnings Call Summary

Moby summary of Annexon, Inc.'s Q2 2026 earnings call

3 週前 · MarketBeat

Annexon Q2 Earnings Call Highlights

Annexon (NASDAQ:ANNX) said it expanded its pivotal ARCHER II trial of vonaprument in geographic atrophy, adding an independent 24-month dual primary endpoint alongside the study’s existing 15-month pr...

第 1 頁，共 2 頁